Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic–Pharmacogenetic Model of HIV-infected Patients in Thailand

Dosage Optimization of Efavirenz Based on a Population Pharmacokinetic–Pharmacogenetic Model of HIV-infected Patients in Thailand

© 2020 Elsevier Inc. Purpose: Efavirenz exhibits high interindividual variability in plasma concentrations, leading to unpredictable efficacy and toxicity. Polymorphism of CYP2B6 516G > T has been found to predominantly contribute to efavirenz variability. However, dosage recommendations incorpor...

Saved in:

書目詳細資料
Main Authors:	Piyawat Chaivichacharn, Anchalee Avihingsanon, Weerawat Manosuthi, Sasiwimol Ubolyam, Siraprapa Tongkobpetch, Vorasuk Shotelersuk, Baralee Punyawudho
格式:	雜誌
出版:	2020
主題:	Medicine Pharmacology, Toxicology and Pharmaceutics
在線閱讀:	https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85085047562&origin=inward http://cmuir.cmu.ac.th/jspui/handle/6653943832/70818
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis of tenofovir in Thai HIV-infected patients
由: Kanokrat Rungtivasuwan, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients
由: Noppaket Singkham, et al.
出版: (2022)

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Impact of pharmacogenetic markers of CYP2B6, clinical factors, and drug-drug interaction on efavirenz concentrations in HIV/tuberculosis-coinfected patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Population pharmacokinetics of tenofovir in HIV/HBV co-infected patients
由: Baralee Punyawudho, et al.
出版: (2018)

Effect of efavirenz on the Pharmacokinetics of Ketoconazole in HIV-infected patients
由: Somchai Sriwiriyajan
出版: (2006)

Effect of efavirenz on the pharmacokinetics of ketoconazole in HIV-infected patients
由: Somchai Sriwiriyajan, et al.
出版: (2006)

Pharmacogenetics: Role in modifying drug dosage regimens
由: Mah, J.T.L., et al.
出版: (2014)

Pharmacokinetic interaction between efavirenz and itraconazole in HIV-infected patients
由: Kritsana Kongklao
出版: (2014)

Body weight cutoff for daily dosage of efavirenz and 60-week efficacy of efavirenz-based regimen in human immunodeficiency virus and tuberculosis coinfected patients receiving rifampin
由: Weerawat Manosuthi, et al.
出版: (2018)

Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases
由: Buddharat Khan-Asa, et al.
出版: (2020)

Impact of albumin and omeprazole on steady-state population pharmacokinetics of voriconazole and development of a voriconazole dosing optimization model in thai patients with hematologic diseases
由: Buddharat Khan-Asa, et al.
出版: (2020)

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults
由: Chonlaphat Sukasem, et al.
出版: (2018)

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults
由: Sukasem C., et al.
出版: (2014)

Pharmacogenetic markers of CYP2B6 associated with efavirenz plasma concentrations in HIV-1 infected Thai adults
由: Chonlaphat Sukasem, et al.
出版: (2018)

Does pregnancy affect the pharmacokinetics of efavirenz?
由: Andrew Hill, et al.
出版: (2018)

Does pregnancy affect the pharmacokinetics of efavirenz?
由: Andrew Hill, et al.
出版: (2018)

Does pregnancy affect the pharmacokinetics of efavirenz?
由: Hill A., et al.
出版: (2014)

Effect of phenytoin on the pharmacokinetics of efavirenz in rabbits
由: Gornganok Piboonpol
出版: (2013)

Efavirenz 600 mg/day versus efavirenz 800 mg/day in HIV-infected patients with tuberculosis receiving rifampicin: 48 Weeks results
由: Weerawat Manosuthi, et al.
出版: (2018)

Personalized medicine in ophthalmology: From pharmacogenetic biomarkers to therapeutic and dosage optimization
由: Ong, F.S, et al.
出版: (2020)

Incidence and risk factors of rash associated with efavirenz in HIV-infected patients with preceding nevirapine-associated rash
由: Weerawat Manosuthi, et al.
出版: (2018)

Population pharmacokinetics and dose optimisation of ritonavir-boosted atazanavir in Thai HIV-infected patients
由: Punyawudho B., et al.
出版: (2017)

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
由: Anthony T. Podany, et al.
出版: (2018)

Efavirenz Pharmacokinetics and Pharmacodynamics in HIV-Infected Persons Receiving Rifapentine and Isoniazid for Tuberculosis Prevention
由: Anthony T. Podany, et al.
出版: (2018)

Efavirenz pharmacokinetics during pregnancy and infant washout
由: Regis Kreitchmann, et al.
出版: (2019)

Significant pharmacokinetic interactions between artemether/lumefantrine and efavirenz or nevirapine in HIV-infected Ugandan adults
由: Pauline Byakika-Kibwika, et al.
出版: (2018)

Successful viral suppression with subsequent efavirenz-based regimen in HIV-1-infected patients who stop nevirapine prior to discontinuation of the NRTI backbone
由: Sukanya Chimsuntorn, et al.
出版: (2018)

Pharmacogenetics-based population pharmacokinetic analysis for dose optimization of ritonavir-boosted atazanavir in Thai adult HIV-infected patients
由: Singkham N.
出版: (2023)

Two novel EBP mutations in Conradi-Hünermann-Happle syndrome
由: Surasawadee Ausavarat, et al.
出版: (2018)

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
由: Tim R. Cressey, et al.
出版: (2018)

Efavirenz pharmacokinetics during the third trimester of pregnancy and postpartum
由: Cressey T., et al.
出版: (2017)

Comparison of thai government manufactured tenofovir (Tenofovir GPO300) with privately manufactured tenofovir (Viread) used along with lamivudine and efavirenz to treat Thai HIV patients
由: Weerawat Manosuthi, et al.
出版: (2018)

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy
由: Zeruesenay Desta, et al.
出版: (2020)

PHARMACODYNAMICS, PHARMACOKINETICS AND PHARMACOGENETICS OF DOXORUBICIN IN SINGAPOREAN BREAST CANCER PATIENTS
由: FAN LU
出版: (2011)

CYP2B6 haplotype and biological factors responsible for hepatotoxicity in HIV-infected patients receiving efavirenz-based antiretroviral therapy
由: Weerawat Manosuthi, et al.
出版: (2018)